WHY US

Partner with us for Press release distribution and get best in class service, guaranteed postings on tier 1 media and maximum reach

(BW)(NJ-INTERCURE)

Korean FDA Approves InterCure's Breakthrough Therapeutic Breathing Device To Lower Blood Pressure

  • Thursday, April 8, 2004 2:30PM IST (9:00AM GMT)
BIOWIRE2K . Millions of Koreans with High Blood Pressure Can Now Benefit from the Innovative Non-Drug Medical Device Available Through ILYANG Pharm Co., Ltd.
 
Seoul, Korea:  Millions of South Koreans with high blood pressure can now benefit from the first non-drug medical device clinically proven to reduce high blood pressure without side effects. InterCure, Inc. and its Korean partner, ILYANG Pharm. Co., Ltd. (KSE: 07570), Wednesday announced that the device, RESPeRATE(R) has received clearance from the Korean Food and Drug Administration (KFDA) for over-the-counter distribution.

The Interactive Respiratory Pacing technology used in RESPeRATE is based upon the established scientific evidence that certain breathing exercises, when performed routinely, can lower blood pressure. These therapeutic breathing exercises are difficult to perform properly without the interactive, personalized coaching that RESPeRATE provides.

RESPeRATE has been clinically validated to significantly lower blood pressure by an average of 14 mmHg systolic and 9 mmHg diastolic after 8 weeks of routine use (15 minutes per day, 3-4 times per week). "The benefits of paced breathing are well established by our traditional Korean medicine. Effectively delivering them by a tested medical device, RESPeRATE is a real breakthrough and an important new non-drug option for the adjunctive treatment of high blood pressure," said Tae Sook Yoo, CEO of IL YANG Pharm. "We have already received a surprisingly large number of inquiries from both physicians and patients, and now that we have received the formal marketing approval, we will do our best to fulfill the expected demand for the product in the coming weeks and months."

"We are thrilled that our partner ILYANG Pharm was able to receive the market approval of the Korean FDA," said Erez Gavish, President and CEO of InterCure. "Physicians and patients in South Korea will finally have access to this remarkable non-drug, no-side-effects hypertension treatment option that is already available in the US and Europe."

RESPeRATE is now available in South Korea by calling ILYANG Pharm at +82.2.522.3572 or online at www.resperatekorea.com.

About InterCure

InterCure is a medical device company that creates and sells products that harness the therapeutic power of breathing for the treatment of hypertension, heart failure, respiratory diseases and other conditions.

InterCure's first product, RESPeRATE(R), is the first medical device ever to be cleared by the FDA for the treatment of hypertension. More information is available at www.intercure.com.

About IL YANG

Founded in 1946, IL YANG Pharmaceutical Co., Ltd. is a global pharmaceutical company headquartered in Korea and listed on the Korean Stock Exchange (KSE: 07570). IL YANG specializes in the field of gastrointestinal and urological disorders and cardiovascular disease with a large array of compounds on the market. More information is available at www.ilyang.co.kr.


Submit your press release

Copyright © 2022 Business Wire India. All Rights Reserved.